|30th October 2020||Jonathan Schechter||25,000||Open or private purchase||$0.98||$24,442.50|
|22nd October 2020||Jonathan Schechter||25,000||Open or private purchase||$1.10||$27,500.00|
|21st October 2020||Jonathan Schechter||22,988||Open or private purchase||$1.10||$25,286.80|
|20th October 2020||Jonathan Schechter||2,012||Open or private purchase||$1.10||$2,213.20|
|16th October 2020||Joshua Silverman||50,000||Open or private purchase||$1.09||$54,445.00|
|15th October 2020||Joshua Silverman||50,000||Open or private purchase||$1.07||$53,315.00|
|28th May 2020||Joshua Silverman||9,756||Grant/award etc.||$0.00|
|1st January 2020||Joshua Silverman||5,201||Exercise of derivative||$0.00|
|27th August 2019||Joshua Silverman||14,972||Payment by withholding||$0.78||$11,678.16|
|27th August 2019||Joshua Silverman||75,950||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Neurotrope, Inc. engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease.